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What Kind of Fungi Are Pneumocystis?
Members of the genus Pneumocystis are microscopic yeast-like
fungi that reside in the lungs of almost every mammal that has
been evaluated for their presence. They grow extracellularly in the
alveoli of mammals and are considered to be host obligate, as they
cannot grow outside the lung on artificial media. Pneumocystis
species (spp.) are typically restricted to the lungs, although extra-
pulmonary manifestations have been reported [1]. Considered to
be zoonotic (able to infect more than one mammalian species),
these organisms once were referred to as a single genus and
species, ‘‘Pneumocystis carinii’’. It is now clear that distinct species of
Pneumocystis infect different mammalian hosts. Each mammalian
species has at least one species of Pneumocystis that it harbors which
cannot infect another mammalian species (species specificity).
Pneumocystis spp. have suffered many identity crises, beginning
with their initial identification in 1909, when they were thought to
be part of the life cycle of the protozoan parasite Trypanosoma cruzi
[2]. In 1914, they were provided an identity of their own and given
the genus and species designation ‘‘Pneumocystis carinii’’, which
reflected their preference for the lung, ‘‘pneumo’’-; their character-
istic morphological form, the cyst, -‘‘cystis’’; and ‘‘carinii’’ to honor
the Italian investigator, Antonio Carini, who provided the slides
for study. Presumed to be a protozoan parasite, the potential
fungal nature of P. carinii was first raised in the 1950s, and the
controversy over their protozoan or fungal nature continued into
the late 20th century [1,2]. Phylogenetic analyses first based on the
nuclear small subunit rRNA sequence alignments then with
additional gene sequence comparisons showed that the closest
extant relatives to P. carinii were the fission yeast Schizosaccharomyces
pombe and the plant pathogen Taphrina deformans [3].
Molecular biological techniques have been essential for
providing the breadth of knowledge that is currently available
for these intractable fungi. Phylogenetic determinations based on
gene sequences not only permitted the fungal identity of the genus
to be clarified, but provided the basis for species distinctions within
the genus. Although it is anticipated that there are thousands of
Pneumocystis species, only five have been formally described: P.
carinii and Pneumocystis wakefieldiae, which infect rats; Pneumocystis
murina in mice; Pneumocystis oryctolagi in rabbits; and Pneumocystis
jirovecii, which infects humans [2].
It should be noted that the nomenclature of Pneumocystis has not
been without controversy, particularly with the name P. jirovecii [2].
A number of clinician investigators raised concerns about the
change from P. carinii to P. jirovecii, which had the potential to cause
confusion among patients and clinicians alike [4]. However,
validation of the names through the formal guidelines recom-
mended by the fungal community combined with scientific and
biological evidence and recommendations by authorities have
contributed to a general acceptance of the current nomenclature,
including P. jirovecii [5].
Where Are They Found and How Do They
Replicate?
Pneumocystis spp. are considered ubiquitous fungi and are found
in the lungs of terrestrial mammals from almost all geographic
regions with the possible exception of the Arctic and Antarctica,
where their presence has not yet been surveyed. Definitive studies
of Pneumocystis in marine mammals have not been reported. No
environmental forms of Pneumocystis have been identified providing
additional evidence that they are dependent upon their hosts for
growth and transmission without need of an intermediate vector or
requirement for maturation outside mammals. Human beings
develop antibodies to P. jirovecii by the age of 4 years, but likely are
exposed at a much earlier age [1]. The first exposure during the
neonatal period seems to result in mild or no clinical symptoms
and is probably mistaken for another infectious agent [6].
Experiments using newborn rats showed that DNA from P. carinii
was present in their oral cavities 1–2 hours after birth, even before
the first feeding, providing evidence that mammals contact
Pneumocystis early in life [7]. This first contact may be by an
airborne route where an infectious propagule is inhaled by the
neonate or by intimate contact such as grooming.
The life cycle of Pneumocystis has not been completely defined,
but most putative schemes contain an asexual mode of replication
via binary fission of the trophic form and a sexual mode resulting
in formation of an ascus (cyst) containing eight ascospores
(Figure 1). Unlike most other yeast, Pneumocystis spp. do not
undergo budding. Mating is likely mediated by the trophic forms,
as evidenced by the expression of a pheromone receptor protein
on the surface of some trophs [8]. Besides the cyst and trophic
forms, there are several intermediate stages that likely represent
the progression from zygote through meiosis with an additional
mitotic step to produce eight nuclei, followed by separation into
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distinct from other medically significant fungi because they appear
to undergo sexual replication in their mammalian hosts, who are
then able to transmit the infection, unlike other fungi (e.g.,
Aspergillus) where the host is a dead end.
After inhalation, the infection is thought to be initiated by
attachment of the trophic forms to the Type I pneumocyte in the
host alveoli. Investigators in the field have long pondered the
identity of the infectious propagule without any clear answers.
However, recent studies provide evidence that the cyst may be the
agent of transmission. Treatment of Pneumocystis-infected mice and
rats with echinocandins (drugs that inhibit b-1,3-D-glucan
synthesis) were shown to eliminate cysts, which contain glucan
in their walls [9]. The cyst-depleted animals that contained large
numbers of viable trophic forms were unable to transmit the
infection by the airborne route to uninfected animals, while their
untreated counterparts containing cysts were able to do so,
implicating the cyst as the transmissive particle. The cyst would be
an efficient way to initiate infection, as a single cyst contains eight
spores. Once in the alveoli, clusters of organisms grow out into the
lumen from trophic forms anchored to the Type I cells. The
infection spreads throughout the entire lungs, but the manner in
which the organisms move from alveolus to alveolus is not known.
Recent evidence describing the ability of P. carinii and P. murina to
form biofilms suggests this mechanism may be one way in which
the infection can spread [10].
Are These Fungi Pathogenic and Do They Cause
Disease?
Pneumocystis spp. cause pneumonia in immunologically impaired
mammals, which is oftentimes lethal if untreated. P. jirovecii
pneumonia (PCP) was a leading cause of morbidity and mortality
in patients with AIDS during the last two decades [11]. With the
introduction of highly active anti-retroviral therapy (HAART) in
1996,the incidenceofPCP hasdecreasedin industrialized countries
like the United States and England, but PCP remains the leading
opportunistic infection among patients with HIV and a serious
clinical problem [12]. Strikingly, the mortality rate associated with
PCP before and after initiation of HAART has not changed
significantly in the US from an average of about 10% [12].
Mortality is even higher in developing countries and within urban
areas of the US, despite the availability of HAART [13]. In HIV-
positive and other immunosuppressed patients with PCP requiring
medical intensive care in Thailand, the mortality rate was about
64%, while in an inner city population in Atlanta, Georgia, the
mortality rate in 1996–2006 was 37%. In patients requiring
aggressive intervention such as mechanical ventilation, the rate
was over 80%. PCP occurs in patients with other immunosuppres-
sive diseases and in those whose immune systems have been
debilitated by drugs such as long-term administration of corticoste-
roids. In fact, there has been little improvement in mortality in
patients with cancer and othernon-HIV diseases,and inmany cases
these patients fared worse than those with HIV. In one study, the
mortality in non-HIV patients from PCP was 48% versus 17% in
individuals with HIV [14]. The recent detection of P. jirovecii in new
patient populations suggests that P. jirovecii is taking advantage of
these evolving niches in the human population. Anti-tumor necrosis
factor-alpha (anti-TNFa) therapy, such as inflixamab, is now
commonly used to treat rheumatoid arthritis and Crohn’s disease. A
Figure 1. Putative life cycle of Pneumocystis. The entry of
Pneumocystis into the mammalian lung likely occurs during the first
year after birth. The agent of infection is suspected to be airborne
spores. Recent studies suggest that the cyst/ascus (containing eight
spores) may be the agent of infection [9]. After inhalation, the spores
ultimately take residence in the terminal portion of the respiratory tree,
the alveoli. Neither the mechanism of migration to the alveoli nor the
form in which the organism arrives in the alveoli (intact ascus or
individual spores) is known. (A) Asexual phase: Haploid trophic forms
are thought to replicate asexually by binary fission, whereby the nuclear
content is duplicated (1) along with cellular contents that (2) divide into
two haploid trophic forms. (B) Sexual phase: Two presumptive mating
types conjugate (1), undergo karyogamy (2), and produce a diploid
zygote (3) that progresses through meiosis to produce four haploid
nuclei (4) followed by an additional mitosis to produce eight nuclei (5).
The nuclei are packaged into spores by invagination of the ascus cell
membranes (6) to produce eight double-membrane spores (7). After
completion, excystment occurs via a protunicate release by unknown
mechanisms (8). The released spores become the vegetative forms that
can then undergo asexual (9) or sexual replication with a presumed
opposite mating type (10). The mechanism of exit out of the lung and
the life cycle form that transits into the environment are unknown (the
life cycle was composed using SmartDraw 10, San Diego, California).
doi:10.1371/journal.ppat.1001009.g001
Figure 2. P. murina stained with rapid Wright-Giemsa. Clusters of
P. murina from a homogenate of an infected mouse lung were dropped
on glass slides and stained with a rapid Wright-Giemsa. The black arrow
points to a cluster of trophic forms. The white arrow indicates a mature
cyst. The yellow arrow indicates an immature cyst with only three nuclei
present in this section. The magnification bar represents 10 um. The
micrograph was taken with an Olympus BH2 microscope and DP-72
digital camera.
doi:10.1371/journal.ppat.1001009.g002
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Event Reporting System for P. jirovecii pneumonia from 1998
through 2003 identified 84 cases of PCP associated with inflixamab
therapy, 27% of which resulted in death [15].
Standard antifungal drugs targeting ergosterol and ergosterol
biosynthesis, such as amphotericin B and the azoles, are not effective
against PCP [11]. The first-line treatment for PCP is the
combination of the anti-folate inhibitors trimethoprim-sulfamethox-
azole (TMP-SMX) together with corticosteroids to reduce destruc-
tive inflammation. There are significant problems associated with
this regimen such as treatment failures and severe rash, fever, and
neutropenia that often necessitate a change to alternative treatment.
Treatment with corticosteroids is a double-edged sword. While it is
recommended for hypoxemic patients with PCP [16], chronic
steroidusage is associated with a higherrate of colonization and with
mortality, especially in non-HIV patients [14]. Second-line therapies
such as clindamycin-primaquine, atovaquone, or pentamidine have
high ratesof relapse and recurrence.Pentamidine hassignificantside
effects, including nephrotoxicity. Currently, there are no new drugs
for PCP in the pipeline. Recent studies of the new class of
antifungals, the echinocandins, have shown selective elimination of
thecystform,withlargepopulationsoftrophicformsremainingafter
treatment [9]. Although clinical use of these compounds has met
with mixed results, it is possible that a combination of an
echinocandin with lower doses of the more toxic agents to eliminate
the trophic forms may provide an effective treatment.
Do They Always Cause Disease?
All of the current information on the life cycle of Pneumocystis
spp. has been derived from the study of organisms in the lungs of
mammals with debilitated immune systems. No information is
available on the life cycle in the non-immunosuppressed host,
where their widespread presence has been confirmed in commer-
cial animal colonies [17] and in the general population of human
beings [13]. Current evidence suggests Pneumocystis can exist with
little consequence to hosts with intact immune systems [13,17],
which may represent a commensal-type of relationship, although
the length of resident time within the lung is not known. In
commercial colonies of immune intact rats or mice, Pneumocystis is
virtually undetectable by symptomatic manifestations. A survey of
137 rats from three different commercial vendors showed a 98%
prevalence in normal healthy rats [17]. In humans, detection of P.
jirovecii has been associated with underlying immune debilitation,
but rarely in healthy populations [18].
However, colonization, as defined by the presence of P. jirovecii
detected by PCR amplification or histological staining of resected
lung tissue, oropharyngeal or nasopharyngeal washes, or bron-
choalveolar fluids, can be associated with poorer outcomes for the
colonized individuals. The changes in immune function that
support colonization can be subtle, including pregnancy, chronic
lung disease, or even immature immune systems, such as that in
infants [13]. In persons suffering from chronic obstructive
pulmonary disorder (COPD), P. jirovecii was detected by PCR
amplification in resected lung tissue of 36.7% of patients with
severe disease versus 9.1% of control subjects [19]. Although not
the cause of mortality, colonized individuals had more severe
airway obstruction than non-colonized individuals. Once thought
to be a potential cause of sudden infant death syndrome (SIDS) in
infants, subsequent studies of post-mortem tissue from infants who
died from SIDS compared with those who died from other causes
did not support these earlier findings, although approximately one-
third of each group had detectable P. jirovecii [20].
It is likely that the organism replicates at low levels within an
immune intact host, evading the immune system by its vast
repertoire of surface antigens [13]. The balance between the
mammalian host and resident or transient Pneumocystis populations
may occur indefinitely until it is perturbed by debilitation of the
immune system, induced by various means including infectious or
immunosuppressive agents, congenital defects, or malnutrition,
which can then lead to proliferation within the lung alveoli and
eventually a lethal pneumonia if untreated. These fungi could be
considered both opportunistic in self-limiting infections and
pathogenic, taking advantage of the loss of the host’s immune
system to increase in number, which ultimately leads to the host’s
demise. However, it appears that host death is not the intent, since
Pneumocystis rely on the host for proliferation and transmission and
probably have evolved to cause as little damage as possible to this
relationship to ensure their survival.
What Is the Answer to the Question Posed in the
Title?
I would argue the answer is (d). The species specificity and host-
obligate nature of the members of this genus argue for a co-
evolution with their respective mammalian hosts in which their
preferred life style seems to be commensal like. In immunologically
intact mammals, Pneumocystis spp. exert little to no pathogenic
effects and enjoy widespread distribution among their host of
choice. Since the mammalian host appears to be necessary for
Pneumocystis spp. survival and complete life cycle including sexual
replication, it would seem advantageous to keep it alive. Should
the host lose some immune function, by disease or chemothera-
peutic agents, the organisms can take advantage of the decreased
host defenses, as would an opportunist, and enter into a more
aggressive state with detectable colonization, which in some cases
can be associated with clinical symptoms. This phase can be self-
limiting if the immune function does not further decline, or if the
source of immunosuppression is alleviated. More sustained or
severe loss of immune competence by the host permits the
organisms to expand and more extensively invade the lung,
resulting in pneumonia and associated pathogenesis. Pneumocystis is
opportunistic in the sense that it takes advantage of the change in
the host immune response to grow and expand, but the apparent
lack of clinical consequences in immunologically intact hosts, the
host specificity, and the lack of innate virulence factors suggest that
these fungi have adapted to form a compatible relationship rather
than a pathogenic one within their natural habitat, the immune
intact mammalian host.
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